Global Bulletin All News FDA Approval Alert Women in Oncology

Expert Conversations Shows & Podcasts News & Analysis

All Journals Editorial Board For Authors Year in Review

More

Events

Frontline Forum Satellite Sessions

Awareness Month The Bispecifics Network Nurse Practitioners/Physician's Assistants Partners Sponsored Sponsored Media

Subscribe

News
Watch
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Adverse Effects
Artificial Intelligence
Brain Cancer
Breast Cancer
- HER2-Positive Breast Cancer
- Triple-Negative Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancer
Hematologic Oncology
Infection
- Vaccines
Leukemia
Lung Cancer
- Small Cell Lung Cancer (SCLC)
- Non-Small Cell Lung Cancer (NSCLC)
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Psycho-Oncology
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer

Spotlight -

Psycho-Oncology|

Artificial Intelligence|

Radiation Oncology|

Advertisement

Meghan S. Karuturi

Advertisement

Articles by Meghan S. Karuturi

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

ByGabrielle Rocque,Joanne L. Blum, MD, PhD,Yan Ji,Eric Gauthier,Yao Wang,Monica Z. Montelongo,Joseph C. Cappelleri,Connie Chen,Meghan S. Karuturi,Debu Tripathy, MD

July 24th 2024

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

ByDebu Tripathy, MD,Joanne L. Blum, MD, PhD,Meghan S. Karuturi,Monica Z. Montelongo,Zhe Zhang,Eric Gauthier,Gabrielle Rocque

June 25th 2024

Advertisement

Latest Updated Articles

Advertisement

Advertisement

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2026 MJH Life Sciences^®

All rights reserved.